AcouSort AB (publ) (ACOU.ST)
SEK 3.49
(-6.18%)
SEK 3.49
(-6.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 34.51 Million SEK | -19.09% |
| 2022 | 42.65 Million SEK | 16.67% |
| 2021 | 36.56 Million SEK | 177.58% |
| 2020 | 13.17 Million SEK | 63.92% |
| 2019 | 8.03 Million SEK | -53.93% |
| 2018 | 17.43 Million SEK | 252.52% |
| 2017 | 4.94 Million SEK | -58.91% |
| 2016 | 12.03 Million SEK | 4517.9% |
| 2015 | 260.7 Thousand SEK | -71.67% |
| 2014 | 920.08 Thousand SEK | -61.88% |
| 2013 | 2.41 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 28.06 Million SEK | -18.67% |
| 2024 Q2 | 25.04 Million SEK | -10.78% |
| 2023 Q2 | 22.03 Million SEK | -14.49% |
| 2023 FY | 34.51 Million SEK | -19.09% |
| 2023 Q4 | 34.51 Million SEK | 114.97% |
| 2023 Q1 | 25.76 Million SEK | -39.59% |
| 2023 Q3 | 16.05 Million SEK | -27.14% |
| 2022 Q2 | 29.94 Million SEK | -10.92% |
| 2022 FY | 42.65 Million SEK | 16.67% |
| 2022 Q4 | 42.65 Million SEK | 71.06% |
| 2022 Q1 | 33.61 Million SEK | -8.06% |
| 2022 Q3 | 24.93 Million SEK | -16.71% |
| 2021 Q4 | 36.56 Million SEK | 460.48% |
| 2021 Q2 | 9.83 Million SEK | -8.82% |
| 2021 Q1 | 10.79 Million SEK | -18.07% |
| 2021 Q3 | 6.52 Million SEK | -33.7% |
| 2021 FY | 36.56 Million SEK | 177.58% |
| 2020 Q1 | 6.27 Million SEK | -21.93% |
| 2020 Q3 | 14.5 Million SEK | -15.83% |
| 2020 FY | 13.17 Million SEK | 63.92% |
| 2020 Q4 | 13.17 Million SEK | -9.22% |
| 2020 Q2 | 17.23 Million SEK | 174.78% |
| 2019 Q1 | 15.92 Million SEK | -8.66% |
| 2019 Q3 | 10.8 Million SEK | -15.45% |
| 2019 Q4 | 8.03 Million SEK | -25.65% |
| 2019 FY | 8.03 Million SEK | -53.93% |
| 2019 Q2 | 12.78 Million SEK | -19.75% |
| 2018 Q3 | 20.66 Million SEK | -8.55% |
| 2018 FY | 17.43 Million SEK | 252.52% |
| 2018 Q4 | 17.43 Million SEK | -15.61% |
| 2018 Q2 | 22.59 Million SEK | 625.43% |
| 2018 Q1 | 3.11 Million SEK | -37.03% |
| 2017 Q3 | 6.96 Million SEK | -16.37% |
| 2017 Q4 | 4.94 Million SEK | -29.01% |
| 2017 FY | 4.94 Million SEK | -58.91% |
| 2017 Q2 | 8.33 Million SEK | -15.2% |
| 2017 Q1 | 9.82 Million SEK | -18.37% |
| 2016 FY | 12.03 Million SEK | 4517.9% |
| 2016 Q4 | 12.03 Million SEK | 599.13% |
| 2016 Q3 | 1.72 Million SEK | 0.0% |
| 2015 Q4 | 260.7 Thousand SEK | 0.0% |
| 2015 FY | 260.7 Thousand SEK | -71.67% |
| 2014 FY | 920.08 Thousand SEK | -61.88% |
| 2013 FY | 2.41 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | 71.984% |
| Amniotics AB (publ) | 26.08 Million SEK | -32.305% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -467.928% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.09% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.184% |
| Saniona AB (publ) | 64.14 Million SEK | 46.194% |
| Simris Alg AB (publ) | 174.55 Million SEK | 80.228% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 93.045% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -132.114% |
| NextCell Pharma AB | 81.28 Million SEK | 57.542% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -14.384% |
| Active Biotech AB (publ) | 44 Million SEK | 21.561% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 70.863% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.191% |
| Cantargia AB (publ) | 223.71 Million SEK | 84.573% |
| Genovis AB (publ.) | 288.85 Million SEK | 88.052% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 59.505% |
| Mendus AB (publ) | 755.95 Million SEK | 95.434% |
| Kancera AB (publ) | 65.64 Million SEK | 47.423% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.257% |
| LIDDS AB (publ) | 17.65 Million SEK | -95.486% |
| Lipum AB (publ) | 12.11 Million SEK | -184.996% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -2.711% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 87.618% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -72.212% |
| OncoZenge AB (publ) | 20.34 Million SEK | -69.68% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 94.719% |
| Xintela AB (publ) | 18.39 Million SEK | -87.622% |
| Ziccum AB (publ) | 14.97 Million SEK | -130.517% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 75.453% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 95.49% |
| CombiGene AB (publ) | 120.61 Million SEK | 71.385% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 84.098% |
| Intervacc AB (publ) | 259.61 Million SEK | 86.706% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 44.67% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 17.746% |
| Corline Biomedical AB | 100.1 Million SEK | 65.523% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 80.514% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 44.47% |
| Aptahem AB (publ) | 63.02 Million SEK | 45.239% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 90.177% |
| Fluicell AB (publ) | 9.34 Million SEK | -269.518% |
| Biovica International AB (publ) | 131.4 Million SEK | 73.736% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 34.863% |
| Abliva AB (publ) | 87.49 Million SEK | 60.556% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 95.46% |
| 2cureX AB (publ) | 16.62 Million SEK | -107.597% |
| I-Tech AB | 152.44 Million SEK | 77.36% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 96.61% |
| Cyxone AB (publ) | 43.65 Million SEK | 20.941% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 56.142% |
| Biosergen AB | 7.2 Million SEK | -379.281% |
| Nanologica AB (publ) | 77.42 Million SEK | 55.426% |
| SynAct Pharma AB | 228.01 Million SEK | 84.864% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -28.958% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 97.535% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -59.025% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 85.522% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -308.196% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 60.363% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -21.064% |